CA2966907C - Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome - Google Patents

Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome Download PDF

Info

Publication number
CA2966907C
CA2966907C CA2966907A CA2966907A CA2966907C CA 2966907 C CA2966907 C CA 2966907C CA 2966907 A CA2966907 A CA 2966907A CA 2966907 A CA2966907 A CA 2966907A CA 2966907 C CA2966907 C CA 2966907C
Authority
CA
Canada
Prior art keywords
formulation
growth hormone
katp channel
drug
diazoxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2966907A
Other languages
English (en)
French (fr)
Other versions
CA2966907A1 (en
Inventor
Neil M. Cowen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Essentialis Inc
Original Assignee
Essentialis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Essentialis Inc filed Critical Essentialis Inc
Priority to CA3125839A priority Critical patent/CA3125839C/en
Priority to CA3125835A priority patent/CA3125835C/en
Publication of CA2966907A1 publication Critical patent/CA2966907A1/en
Application granted granted Critical
Publication of CA2966907C publication Critical patent/CA2966907C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • C07D285/20—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems
    • C07D285/22—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15—Six-membered rings
    • C07D285/16—Thiadiazines; Hydrogenated thiadiazines
    • C07D285/18—1,2,4-Thiadiazines; Hydrogenated 1,2,4-thiadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2966907A 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome Active CA2966907C (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA3125839A CA3125839C (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
CA3125835A CA3125835C (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201462080150P 2014-11-14 2014-11-14
US62/080,150 2014-11-14
US201562138245P 2015-03-25 2015-03-25
US62/138,245 2015-03-25
US201562170035P 2015-06-02 2015-06-02
US62/170,035 2015-06-02
US201562221359P 2015-09-21 2015-09-21
US62/221,359 2015-09-21
PCT/US2015/060455 WO2016077629A1 (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CA3125839A Division CA3125839C (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
CA3125835A Division CA3125835C (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Publications (2)

Publication Number Publication Date
CA2966907A1 CA2966907A1 (en) 2016-05-19
CA2966907C true CA2966907C (en) 2021-09-07

Family

ID=55955075

Family Applications (4)

Application Number Title Priority Date Filing Date
CA3125835A Active CA3125835C (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
CA3210794A Pending CA3210794A1 (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
CA3125839A Active CA3125839C (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
CA2966907A Active CA2966907C (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Family Applications Before (3)

Application Number Title Priority Date Filing Date
CA3125835A Active CA3125835C (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
CA3210794A Pending CA3210794A1 (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
CA3125839A Active CA3125839C (en) 2014-11-14 2015-11-12 Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Country Status (19)

Country Link
US (8) US10058557B2 (OSRAM)
EP (1) EP3217963B1 (OSRAM)
JP (4) JP6709226B2 (OSRAM)
KR (4) KR102517840B1 (OSRAM)
CN (2) CN107106500B (OSRAM)
AU (2) AU2015346196B2 (OSRAM)
BR (1) BR112017009986A2 (OSRAM)
CA (4) CA3125835C (OSRAM)
DK (1) DK3217963T3 (OSRAM)
EA (1) EA036103B1 (OSRAM)
ES (1) ES2806977T3 (OSRAM)
HU (1) HUE050895T2 (OSRAM)
IL (1) IL252111B (OSRAM)
MX (2) MX381305B (OSRAM)
MY (1) MY187610A (OSRAM)
NZ (1) NZ768958A (OSRAM)
PL (1) PL3217963T3 (OSRAM)
SG (1) SG11201703721SA (OSRAM)
WO (1) WO2016077629A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2404605B1 (en) 2004-08-25 2015-04-22 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
ES2984297T3 (es) 2006-01-05 2024-10-29 Essentialis Inc Sales de abertura de canales ATP de potasio y usos de las mismas
MY187610A (en) 2014-11-14 2021-10-04 Essentialis Inc Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
AU2017275652B2 (en) 2016-06-03 2023-02-16 Levo Therapeutics, Inc. Methods of treating Prader-Willi syndrome
CA3062170A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
AU2019345166B2 (en) * 2018-09-20 2021-09-02 Levo Therapeutics, Inc. Stable intranasal formulations of carbetocin
CN111888330B (zh) * 2020-09-18 2022-08-16 常州市第四制药厂有限公司 一种二氮嗪口服混悬溶液及制备方法
TW202430507A (zh) * 2022-10-18 2024-08-01 美商律森製藥股份有限公司 新穎atp-敏感性鉀通道增效劑、其製備及用途
WO2025057119A1 (en) * 2023-09-15 2025-03-20 Soleno Therapeutics, Inc. Methods of managing glycemic control in prader-willi syndrome patients

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2986573A (en) 1961-01-18 1961-05-30 Schering Corp Method for the treatment of hypertension
GB8601204D0 (en) 1986-01-18 1986-02-19 Boots Co Plc Therapeutic agents
GB2186485B (en) 1986-02-13 1988-09-07 Ethical Pharma Ltd Slow release formulation
US5284845A (en) 1991-03-14 1994-02-08 Paulsen Elsa P Use of oral diazoxide for the treatment of disorders in glucose metabolism
US5629045A (en) 1992-09-17 1997-05-13 Richard L. Veech Biodegradable nosiogenic agents for control of non-vertebrate pests
US5399359A (en) 1994-03-04 1995-03-21 Edward Mendell Co., Inc. Controlled release oxybutynin formulations
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US6225310B1 (en) * 1996-01-17 2001-05-01 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
WO1998010786A2 (en) 1996-09-12 1998-03-19 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
US6197765B1 (en) 1999-06-08 2001-03-06 Pnina Vardi Use of diazoxide for the treatment of metabolic syndrome and diabetes complications
WO2002000222A1 (en) 2000-06-26 2002-01-03 Novo Nordisk A/S Use of potassium channel agonists for the treatment of cancer
TW478039B (en) 2001-04-09 2002-03-01 Promos Technologies Inc Phase shift alignment system
US6669955B2 (en) 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6960346B2 (en) 2002-05-09 2005-11-01 University Of Tennessee Research Foundation Vehicles for delivery of biologically active substances
US20040143213A1 (en) 2002-11-12 2004-07-22 Collegium Pharmaceutical, Inc. Inertial drug delivery system
US20040204472A1 (en) 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
CA2571717A1 (en) * 2004-06-23 2006-01-05 Josette-Nicole Mahy Gehenne Compounds for the treatment of inflammation of the central nervous system
CN101043879A (zh) * 2004-08-25 2007-09-26 伊森舍丽斯有限公司 钾atp通道开放剂的药物制剂及其应用
EP2404605B1 (en) 2004-08-25 2015-04-22 Essentialis, Inc. Pharmaceutical formulations of potassium ATP channel openers and uses thereof
WO2006045799A2 (en) * 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising cb1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type i, obesity and related conditions
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
CN101257897A (zh) * 2005-07-07 2008-09-03 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
ES2984297T3 (es) 2006-01-05 2024-10-29 Essentialis Inc Sales de abertura de canales ATP de potasio y usos de las mismas
CA2655144A1 (en) * 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
US20120238554A1 (en) 2007-07-02 2012-09-20 Cowen Neil M Salts of potassium atp channel openers and uses thereof
AU2008272923A1 (en) * 2007-07-02 2009-01-08 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US20120053172A1 (en) * 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
RS58237B1 (sr) * 2011-12-15 2019-03-29 Millendo Therapeutics Sas Fragmenti neacilovanog grelina za upotrebu u lečenju prader-willi sindroma
WO2013130411A1 (en) 2012-02-27 2013-09-06 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
JP2014074004A (ja) * 2012-10-05 2014-04-24 Shinichi Niijima 精神症状の改善剤
US20140364367A1 (en) 2013-06-08 2014-12-11 Sedogen, Llc Methods of treating prader willi syndrome and conditions associated with low basal metabolic rate or hyperphagia using a katp channel opener
MY187610A (en) 2014-11-14 2021-10-04 Essentialis Inc Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome

Also Published As

Publication number Publication date
US20180021344A1 (en) 2018-01-25
EA036103B1 (ru) 2020-09-29
MY187610A (en) 2021-10-04
WO2016077629A1 (en) 2016-05-19
US10874676B2 (en) 2020-12-29
PL3217963T3 (pl) 2020-10-19
CA3210794A1 (en) 2016-05-19
US20200147100A1 (en) 2020-05-14
CN107106500A (zh) 2017-08-29
JP6955039B2 (ja) 2021-10-27
JP7232300B2 (ja) 2023-03-02
AU2015346196A1 (en) 2017-06-29
CN107106500B (zh) 2021-07-30
KR20170082625A (ko) 2017-07-14
JP2017533972A (ja) 2017-11-16
KR20230049760A (ko) 2023-04-13
MX2021003982A (es) 2022-06-09
KR102517840B1 (ko) 2023-04-05
AU2019202906A1 (en) 2019-05-16
US20250120979A1 (en) 2025-04-17
MX2017006244A (es) 2018-02-26
EP3217963B1 (en) 2020-05-20
US20240207284A1 (en) 2024-06-27
EP3217963A4 (en) 2018-07-04
US12178823B1 (en) 2024-12-31
JP2020073566A (ja) 2020-05-14
KR102598666B1 (ko) 2023-11-07
IL252111B (en) 2021-09-30
CA2966907A1 (en) 2016-05-19
CA3125839C (en) 2023-10-24
JP2021193148A (ja) 2021-12-23
BR112017009986A2 (pt) 2018-02-14
KR20210134843A (ko) 2021-11-10
US10456408B2 (en) 2019-10-29
IL252111A0 (en) 2017-07-31
CA3125835A1 (en) 2016-05-19
JP2023056025A (ja) 2023-04-18
HUE050895T2 (hu) 2021-01-28
CA3125839A1 (en) 2016-05-19
US12343348B2 (en) 2025-07-01
US12109216B2 (en) 2024-10-08
US20190105327A1 (en) 2019-04-11
NZ731565A (en) 2021-06-25
EP3217963A1 (en) 2017-09-20
CN113599386A (zh) 2021-11-05
KR20220124289A (ko) 2022-09-13
DK3217963T3 (da) 2020-07-20
KR102323613B1 (ko) 2021-11-09
JP6709226B2 (ja) 2020-06-10
US12419895B1 (en) 2025-09-23
KR102452254B1 (ko) 2022-10-11
EA201791067A1 (ru) 2017-11-30
AU2015346196B2 (en) 2019-01-31
CA3125835C (en) 2023-01-03
CN113599386B (zh) 2025-12-05
US20240423996A1 (en) 2024-12-26
SG11201703721SA (en) 2017-06-29
NZ768958A (en) 2021-07-30
US20210322434A1 (en) 2021-10-21
US10058557B2 (en) 2018-08-28
US20250288593A1 (en) 2025-09-18
MX381305B (es) 2025-03-12
MX393030B (es) 2025-03-24
HK1243954A1 (en) 2018-07-27
AU2019202906B2 (en) 2020-05-21
JP7645913B2 (ja) 2025-03-14
ES2806977T3 (es) 2021-02-19

Similar Documents

Publication Publication Date Title
US12178823B1 (en) Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
EP2404605B1 (en) Pharmaceutical formulations of potassium ATP channel openers and uses thereof
US9757384B2 (en) Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
HK1243954B (en) Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
NZ731565B2 (en) Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome
HK1146390A (en) Pharmaceutical formulations of potassium atp channel openers and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201111